Although cholinesterase inhibitors have been frequently used in the treatment of Alzheimer
disease, its effects on serum cholinesterase concentrations have been rarely described.
We described significant depression of serum cholinesterase levels due to cholinesterase
inhibitor toxicity from redundant use of donepezil and rivastigmine in a 78-year-old
man. Recovery of serum cholinesterase level was noted upon drug discontinuation and
cholinergic symptom resolution. Serum cholinesterase level can be used as a biomarker
for central cholinesterase inhibitor toxicity.
To read this article in full you will need to make a payment
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D; use, select 'Corporate R&D; Professionals'
Subscribe:
Subscribe to The American Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Use of cholinesterase inhibitors in clinical practice: evidence based recommendations.Am J Geriatr Psychiatry. 2003; 11: 131-145
- Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta analysis.CMAJ. 2003; 169: 557-564
- Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.PLoS Med. 2009; 6: e1000157https://doi.org/10.1371/journal.pmed.1000157
- Effects oncholinergic markers in rat brain and blood after short and prolonged administration of donepezil.Neurochem Res. 2005; 30: 1511-1520
- Serum and CSF cholinesterase activity in various kinds of dementia.Eur Arch Psychiatry Neurol Sci. 1987; 236: 309-311
Article Info
Publication History
Published online: January 06, 2014
Accepted:
December 19,
2013
Received in revised form:
December 19,
2013
Received:
December 13,
2013
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
